How do you think the combination b/w SG and LL pro
Post# of 154558
(Total Views: 577)
Posted On: 05/05/2025 5:03:39 PM
Quote:
How do you think the combination b/w SG and LL proves out in the murine study?
Do you think the mOS is increased over SG's 11 months with the addition of LL? to LL's mOS?
Trodelvy binds to Trop-2 on tumor cells than delivers a topoisomerase inhibitor inside the cell that breaks the DNA. Leronlimab has some of that same activity but I think it's low level. However leronlimab has a much broader field of activity than that. Combined it's a one, two punch. Leronlimab itself has already shown to have a longer mOS than Trodelvy.
Quote:
If we were to triple SG's mOS from 11 months to 3 years, would that qualify for novel drug and patent extension?
A 3 year mOS may be overly optimistic given genetic variation but it might be possible. In order to get a new patent it would have to be a drug conjugation. I don't think that's a possibility given that Trodelvy needs to bind to Trop-2 and leronlimab needs to bind seperately to CCR5..
Quote:
[Let's say the offer was for somewhere what they paid for SG, but stipulated with the condition to abandon HIV, how would that go over?/quote]
If they do make a suitable buyout offer than they can do whatever they want with it.
(11)
(0)